Virion Therapeutics Reports Durable Functional Cure Signals in Chronic Hepatitis B with Single-Dose VRON-0200 at EASL 2026
Virion Therapeutics, LLC, a clinical-stage biotechnology company focused on developing next-generation T cell–based immunotherapies for chronic viral diseases, has announced compelling long-term clinical data for its investigational therapy VRON-0200 in chronic hepatitis B virus (HBV) infection. The findings were presented at the 2026 European Association for the Study of the Liver (EASL) Congress in Barcelona, Spain, and highlight sustained antiviral immune activity and prolonged reductions in hepatitis B surface antigen (HBsAg) following a single intramuscular dose of the therapy.
The data were delivered in an oral presentation by Professor Edward Gane, M.D., of the University of Auckland, and represent one of the most extended follow-up datasets reported to date for an immune-modulating therapy targeting functional cure in HBV.
Sustained Immune Activation and Long-Term Viral Control
VRON-0200 is designed as a first-in-class immunotherapy intended to restore HBV-specific immune function through checkpoint modulation and T cell activation. According to the newly presented data, a single intramuscular dose of VRON-0200 triggered measurable HBV-specific immune activation and immune restoration in chronically infected patients.
Importantly, the majority of treated patients demonstrated continued declines in HBsAg levels lasting up to two years after administration, without evidence of viral rebound. This sustained response was observed during long-term follow-up, suggesting that VRON-0200 may help re-establish durable immune control over HBV replication rather than relying solely on continuous antiviral suppression.
In patients who received VRON-0200 in combination with investigational antiviral Virion therapies, sustained reductions in HBsAg were also observed for up to three months after the discontinuation of antiviral treatment, further reinforcing the durability of the immune response.
The absence of rebound after stopping antiviral therapy is particularly significant in chronic HBV management, where viral resurgence is common once treatment is withdrawn.
Expert Interpretation of Functional Cure Potential
Professor Edward Gane highlighted the importance of immune restoration in achieving functional cure in chronic hepatitis B. He noted that while existing antiviral therapies have significantly improved viral suppression, they typically require lifelong administration because they do not fully restore the patient’s immune capacity to control the virus independently.
According to Gane, the VRON-0200 data are notable because they demonstrate sustained HBsAg declines without viral rebound over an extended follow-up period of more than two years in many patients. He emphasized that these results suggest that the therapy may meaningfully enhance endogenous anti-HBV immune responses, which are essential for long-term viral control.
He further noted that the ability of VRON-0200 to restore immune responsiveness may represent an important step toward achieving a finite treatment course that allows patients to discontinue antiviral therapy without relapse, a central goal in the field of HBV cure research.
Mechanism-Based Approach to Immune Restoration
VRON-0200 is part of a new class of immunotherapies designed to address one of the key limitations in chronic HBV infection: immune exhaustion. In chronic infection, HBV-specific T cells become dysfunctional over time, allowing the virus to persist despite antiviral treatment.
The mechanism of VRON-0200 focuses on modulating immune checkpoints to reactivate exhausted T cells and restore antiviral immune function. By stimulating HBV-specific immune responses, the therapy aims to shift disease management from viral suppression to immune-mediated control.
The long-term data presented at EASL suggest that this immune reactivation may not only be immediate but also durable, potentially leading to progressive improvements in viral control over time even after a single administration.
Durable HBsAg Declines Without Rebound
One of the most clinically significant findings from the study is the sustained reduction in HBsAg levels without rebound in the majority of patients who received VRON-0200. HBsAg is a key marker of HBV infection and persistence, and its sustained reduction is considered an important indicator of progress toward functional cure.
The absence of rebound over a follow-up period extending beyond two years suggests that VRON-0200 may induce durable immunological changes rather than transient antiviral effects. This distinguishes it from many existing therapies that require ongoing administration to maintain viral suppression.
These findings support the hypothesis that immune restoration, rather than continuous viral suppression alone, may be required to achieve long-term disease control in chronic HBV infection.
Combination Therapy and Expanded Clinical Development Strategy
The study also evaluated VRON-0200 in combination with investigational antiviral therapies. In these patients, sustained reductions in HBsAg were observed for up to three months following the last dose of antiviral treatment, suggesting that VRON-0200 may help maintain viral suppression even after standard therapy is discontinued.
Based on these results, Virion Therapeutics is developing a Phase 2b clinical study known as SPARK-B. This upcoming trial will evaluate functional cure outcomes following nucleos(t)ide analogue discontinuation in patients treated with VRON-0200.
The planned study will include patients with higher baseline HBsAg levels, defined as less than 3000 IU/mL, expanding the potential patient population beyond those typically considered most responsive to emerging curative approaches.
In addition, VRON-0200 is being explored in other chronic HBV populations, including patients co-infected with HIV/HBV and hepatitis D virus (HDV)/HBV, as well as individuals with metabolic dysfunction-associated steatohepatitis (MASH), reflecting a broader therapeutic strategy for immune-mediated liver disease.
Clinical Expert Perspective on Treatment Landscape
Professor Grace Wong of the Chinese University of Hong Kong, one of the study investigators, emphasized both the progress and the remaining challenges in HBV therapy. She noted that while multiple investigational treatments are advancing toward regulatory approval and have shown improved rates of functional cure, their effectiveness is often limited to specific patient populations, particularly those with lower baseline HBsAg levels.
She also highlighted practical barriers associated with emerging therapies, including complex dosing regimens, safety considerations, tolerability issues, and cost, all of which may limit widespread adoption.
In this context, she described VRON-0200 as particularly promising due to its single-dose intramuscular administration, favorable safety profile, and potential for durable viral control. She emphasized that the therapy’s ability to prevent viral rebound after treatment discontinuation could significantly enhance overall functional cure rates across broader patient populations.
Safety, Tolerability, and Administration Advantages
Across the clinical dataset presented at EASL 2026, VRON-0200 demonstrated a favorable safety and tolerability profile. No new safety signals were reported during long-term follow-up, and the single intramuscular administration route was associated with ease of use and reduced treatment burden compared with chronic daily oral antiviral therapies.
This simplified dosing approach may offer important advantages in real-world clinical settings, particularly in regions with high HBV prevalence where long-term adherence to daily therapy can be challenging.
Strategic Implications for Functional Cure in HBV
The global burden of chronic hepatitis B remains substantial, with an estimated 260 million people living with chronic infection worldwide. Despite the availability of effective antiviral agents, functional cure—defined as sustained viral suppression without ongoing therapy—remains an elusive goal for most patients.
VRON-0200’s ability to induce durable immune responses and sustained reductions in viral markers after a single dose positions it as a potentially transformative approach within the HBV treatment landscape. Its combination of immune restoration, long-lasting activity, and ease of administration may allow it to serve as a backbone therapy either alone or in combination with other emerging agents.
Virion Therapeutics has indicated that VRON-0200 may also be evaluated as part of future combination regimens designed to further enhance functional cure rates.
Access to Data and Next Steps
The full presentation materials from the EASL 2026 Congress are available for download on the company’s website at www.VirionTx.com. Additional study details can also be accessed via ClinicalTrials.gov under the identifier NCT06070051.
As VRON-0200 advances into later-stage clinical development, including the planned Phase 2b SPARK-B study, the therapy will continue to be closely watched as part of the broader effort to achieve functional cure in chronic hepatitis B.
If ongoing and future studies confirm these early findings, VRON-0200 could represent a significant step forward in shifting HBV treatment from lifelong viral suppression toward finite, immune-mediated cure strategies.
About Chronic Hepatitis B
Despite a preventative vaccine, cases of chronic hepatitis B (CHB) continue to rise, with an estimated 254 million persons infected worldwide and 1.1 million deaths per year from HBV-related liver complications. Chronic HBV remains a global health issue with a high unmet medical need since there is no cure available. The current standard of care requires lifelong antiviral therapy to maintain control of the virus.
Current and investigational HBV Functional Cure treatments have been limited by their inability to restore a patient’s own immune responses against the virus. As a result, once treatment is discontinued, and the antiviral agents are no longer present, viral rebound typically occurs. As a result, immune modulators are now considered necessary for future cure treatment strategies.
About VRON-0200
VRON-0200 is an investigational therapeutic immunotherapy designed with the goal of providing a functional cure for chronic HBV infection. Clinical data from an ongoing Phase 1b trial have shown VRON-0200 to be safe and well tolerated, and, when given as a single intramuscular dose, was immunogenic, and able to “Spark” anti-HBV activity in chronically HBV-infected patients on nucleos(t)ide therapy alone, and, also, when given with combination antiviral therapies. These results suggest the potential of VRON-0200 to be a key backbone immune modulator for HBV functional cure treatments.
About Virion Therapeutics (Virion)
Virion Therapeutics, LLC is a clinical-stage company developing novel immunotherapies that utilize proprietary checkpoint modifiers to enhance/restore, broaden, and elicit sustained immune responses, with the goal to cure cancer and chronic infectious diseases. Virion’s pipeline now includes its lead VRON-0200 clinical program, and several additional IND-enabling programs, such as its VRON-0300 oncology program for advanced solid tumors, leveraging its proprietary platform technologies.
